A competitive inhibitor of PDE10A, TAK-063 [16, 17], was administered i.p. beginning 5 days after stroke, a time point at which brain sensitivity to damage-enhancing effects of plasticity drugs is lost [4]. Here, PDE10A is linked to stroke disorder.